Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis. (19th May 2018)

• Record Type: Journal Article
• Authors: Wang, Aihua; Wang, Fengqiang; Yin, Yingqiu; Zhang, Min; Chen, Ping
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46:Number 4(2018)
• Page Start: 783
• Page End: 787
• Publication Date: 2018-05-19
• Subjects: Pulmonary fibrosis -- bleomycin-A5 -- interleukin-8 -- TGF-β1 -- interleukin-17; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2017.1339051
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Background: Pulmonary fibrosis is a chronic progressive disease with limited therapeutic options and inflammatory cytokines play important roles in the pathogenesis of pulmonary fibrosis. Material and method: Here, we investigated the changes of TGF-β1, IL-8, and IL-17 in the serum of bleomycin-A5-induced rats model of pulmonary fibrosis. 120 healthy male Wistar rats were randomly divided into three groups, the control group ( n = 30), the model group ( n = 45) and the dexamethasone (DEX) group ( n = 45). The rats of both model group and DEX group were injected with Bleomycin-A5 (5 mg/kg) through tracheofistulization to induce pulmonary fibrosis, while the rats of the control group were injected with equivalent physiological saline. After operation, DEX (4 mg/kg) was given to the DEX group rats intraperitoneally once a day. Equivalent saline was administered to rats of both the control group and the model group. Results: On the 1st, 14th, and 28th day after operation, pathological changes of the lung tissues, and the levels of serum IL-8, TGF-β1, and IL-17 were measured. The concentrations of serum TGF-β1, IL-8, and IL-17 were significantly increased after bleomycin-A5 treatment, especially on the 14th day ( p < .01). There was no significant difference between model group and DEX group in the serum level of TGF-β1 and IL-8, but DEX treatment significantly reduce serum IL-17 level ( p < .01). Conclusions: DEX protect bleomycin-A5-induced pulmonary fibrosis in rats through reduced the level of IL-17 in serum.